S. Borrmann et al., Artesunate and praziquantel for the treatment of Schistosoma haematobium infections: A double-blind, randomized, placebo-controlled study, J INFEC DIS, 184(10), 2001, pp. 1363-1366
Recently, artemisinin derivatives have been shown to be efficacious in chem
oprophylaxis of and chemotherapy for Schistosoma japonicum and S. mansoni i
nfections. Therefore, a double-blind, randomized, placebo-controlled study
was carried out to investigate the efficacy and tolerability of artesunate
plus placebo and the combination of artesunate and praziquantel in the trea
tment of S. haematobium infections in Gabon. The 300 infected schoolchildre
n included in the study were randomized to receive artesunate plus placebo
(n = 90), praziquantel plus placebo (n = 90), artesunate and praziquantel (
n = 90), or only placebo (). End points were efficacy, assessed as cure on
day 56, and tolerability. All treatment regimens were well tolerated. The p
raziquantel plus placebo-treated group attained a cure rate of 73%, artesun
ate plus placebo a rate of 27%, the combination of artesunate and praziquan
tel a rate of 81%, and placebo alone a rate of 20%. In summary, earlier fin
dings of efficacy of artemisinin derivatives against S. mansoni and S. japo
nicum could not be confirmed in S. haematobium infections.